<DOC>
	<DOC>NCT00874146</DOC>
	<brief_summary>Primary objective of the study is to evaluate the correlation between level of HER2-neu gene amplification evalued by dual-color Fluorescent in-situ hybridization (FISH) test and time to progression (TTP) in patients with HER2-positive advanced breast cancer treated with trastuzumab-containing regimens.</brief_summary>
	<brief_title>Level of HER2-neu Gene Amplification an Response to Trastuzumab</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>HER2positive breast cancer Trastuzumabcontaining regimen delivered for advanced disease Tumor sample available at Pathology Archive HER2negative advanced breast cancer Pretreatment with trastuzumab</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>